Allena Pharmaceuticals to Present Virtually at Evercore ISI 3rd Annual HealthCONx Conference
Allena Pharmaceuticals (NASDAQ: ALNA) announced that its President and CEO, Louis Brenner, M.D., will participate in a virtual fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020, at 1:25 p.m. ET. A live audio webcast will be accessible in the 'Events and Presentations' section on the company's website, with a replay available for 30 days post-presentation.
Allena specializes in developing oral enzyme therapeutics for rare metabolic and kidney disorders, with lead candidate reloxaliase undergoing a pivotal Phase 3 trial for enteric hyperoxaluria.
- None.
- None.
NEWTON, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Louis Brenner, M.D., Allena’s President and Chief Executive Officer, will participate in a virtual fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on Thursday, December 3, 2020, at 1:25 p.m. ET.
A live audio webcast of the presentation will be available under “Events and Presentations” in the Investors section of the Company’s website at www.allenapharma.com. A replay of the webcast will be available on the Allena website for 30 days following the presentation.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders. Allena is also developing ALLN-346, currently being evaluated in a Phase 1 clinical trial, for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease.
Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com
Media Contact
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com
FAQ
When is Louis Brenner's fireside chat for Allena Pharmaceuticals at the Evercore ISI HealthCONx Conference?
Where can I watch the Allena Pharmaceuticals presentation at the Evercore ISI Conference?
What is Allena Pharmaceuticals focusing on in their clinical development?
What is reloxaliase and its significance for Allena Pharmaceuticals?
What is the stock symbol for Allena Pharmaceuticals?
